Pieris Pharmaceuticals

Therapeutics based on recombinant engineered lipocalin mimics

placeBoston, Massachusetts, United States calendar_todayFounded 2001 groups127 employees language pieris.com

Registered entities

Innovation

50 patent families (29 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace slowing. Cited 7,275 times.

YearFilings
20152
20168
201720
201824
201915
202017
202121
202220
202321
202412
20257
20261

Investor mix

26 investors on record; 1 has since exited.

Investor typeCountShare
Venture capital935%
Private equity623%
Bank & private debt14%
Other / undisclosed1038%
Coming soon